When the brain is under attack
An intracranial infection — an infection inside the skull — can include meningitis (infection of the brain's lining), encephalitis (infection of the brain tissue itself), or a brain abscess (a pocket of infection). These conditions can cause permanent brain damage or death if not treated correctly and quickly.
The challenge is that dozens of different pathogens can cause these infections, and each one requires a different treatment. Giving the wrong antibiotic — or missing a viral cause entirely — can cost precious time.
The old way wasn't fast enough
Standard diagnosis relies on cerebrospinal fluid (CSF) cultures — a lab method where fluid from around the brain is grown in a dish to see what organisms appear. This can take 48 to 72 hours, or longer. And some pathogens don't grow well in culture at all.
But here's the twist — a technique called targeted nanopore sequencing (TNPseq) can read the genetic fingerprints of pathogens directly from a patient's sample in a fraction of that time. Instead of waiting for germs to grow, it sequences the DNA and RNA present in the sample and matches it against a database of known pathogens.
Think of it like a barcode scanner at a checkout counter. Instead of trying to identify every item by looking at it, you just scan the label — and the computer tells you exactly what it is, almost instantly.
What the study set out to do
Researchers in China ran a retrospective (looking back at past cases) study of 255 patients admitted with suspected intracranial infections. They used TNPseq to identify pathogens in these patients and then focused on 39 patients who had complete blood test data to explore whether common blood markers could predict disease severity and hospital stay length.
They looked at three blood markers: C-reactive protein (CRP, a sign of inflammation), neutrophil ratio (NR, a measure of immune cell activity), and procalcitonin (PCT, a marker that rises during bacterial infections).
TNPseq successfully identified pathogens across the patient group. The most common ones found were Propionibacterium acnes, Human herpesvirus 4, and Moraxella osloensis — a mix of bacteria and viruses that would be difficult to distinguish without genetic testing.
Among the blood markers, CRP was the best at predicting which patients had a more serious infection. Procalcitonin came second, and neutrophil ratio third. Importantly, the neutrophil ratio was closely linked to how long patients stayed in the hospital — and statistical analysis showed that the neutrophil ratio was the key pathway through which elevated CRP predicted a longer hospital stay.
This means that a simple blood test, combined with genetic sequencing, could help doctors triage patients faster.
If you or someone you love is hospitalized with a suspected brain infection, this research points toward a future where diagnosis is faster and more precise. Right now, TNPseq is not yet standard care in most hospitals. It requires specialized equipment and trained staff. But it is being used in some academic medical centers, and its availability is expanding.
For now, if you are in a hospital with a suspected intracranial infection, ask your care team about all available diagnostic options, especially if standard cultures are coming back unclear.
This study was small — only 39 patients had complete data for the biomarker analysis. It was also retrospective, meaning researchers looked at past records rather than designing a controlled trial. These limitations mean the findings should be seen as promising early evidence, not definitive proof. Larger, prospective studies are needed.
The combination of rapid pathogen sequencing and blood-based inflammatory markers represents a direction that researchers are actively pursuing. As sequencing technology becomes cheaper and faster, it may eventually become a routine part of emergency neurology care. The next step is larger, prospective studies that test this approach in real-time clinical settings — and evaluate whether faster diagnosis actually leads to better patient outcomes, not just faster lab results.
